glp-1 hypertension Potential Use of and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? GLP-1 use linked to fewer

8 Oral medications Because GLP-1 medications slow stomach emptying, the absorption of other oral medications can be slightly delayed

The half-life amounts to approximately 5 days

Among those using medication for weight loss, 15% (about one in seven) were using medication not licensed for this purpose (such as Rybelsus licensed in the UK for type 2 diabetes only)

Full-service restaurants could actually benefit from GLP-1: Spending has increased, suggest a shift from convenience dining toward more experiential or quality-focused dining occasions

Any decision to initiate GLP-1 therapy should involve shared decision-making that weighs individual patient factors, comorbidities, and realistic expectations about potential cognitive benefits

The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects